From: Cost-effectiveness analysis of atezolizumab in advanced triple-negative breast cancer
 | Atezolizumab/nab-paclitaxel | Nab-paclitaxel | Incremental |
---|---|---|---|
PFLYs | 0.856 | 0.566 | 0.290 |
LYs | 2.308 | 1.672 | 0.636 |
QALYs | 1.255 | 0.895 | 0.361 |
Total Costs (S$) | 173,623 | 56,563 | 117,060 |
 Drug and drug administration costs, first-line | 148,311 | 36,688 | 111,623 |
 Drug and drug administration costs, subsequent-lines | 8551 | 8230 | 321 |
 Disease monitoring and management costs | 14,107 | 8645 | 5461 |
 Palliative care costs | 2654 | 3000 | − 345 |
ICER (S$ per LY gained) | Â | Â | 183,965 |
ICER (S$ per QALY gained) | Â | Â | 324,550 |